NP47724 NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A & B (CM/PHS/22/5661)

Description

Supply of products for the treatment of Blood Disorders including Haemophilia A & B to NHS Scotland. Lot 1: Standard Half-life Recombinant Factor VIII NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Lot 2: Enhanced Half-life Recombinant Factor VIII NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Lot 3: Enhanced Half-life Recombinant Factor VIII NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Lot 4: Eftrenonacog alfa (rFIX EHL) NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Lot 5: Eftrenonacog alfa (rFIX EHL) NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Lot 6: Nonacog beta pegol (rFIX EHL) NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Lot 7: rFIX - Standard Half Life NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Lot 8: Recombinant Factor VII NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Lot 9: Porcine Factor VIII - susoctocog alfa NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Lot 10: Factor VIII Inhibitor Bypassing Fraction NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Lot 11: Factor IX - High Purity Factor IX NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Lot 12: Factor X NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Lot 13: Factor XIII - Plasma Derived NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Lot 14: Factor XIII - Recombinant NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Lot 15: Von willebrands factor / Factor VIII NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Lot 16: Von willebrands factor - Plasma Derived NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Lot 17: Von willebrands factor - Recombinant NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Lot 18: Fibrinogen Concentrate NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Lot 19: Prothrombin Complex dried NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Lot 20: Protein C Concentrate NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months. Lot 21: Fresh Frozen Plasma (all blood groups) NHS Framework Agreement (call-off) for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. The Framework Agreement will commence on 01 July 2024 for a period of thirty-four (34) months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of fourteen (14) months.